Selectively Targeting Chromophobe Kidney Cancer Tumors

1 Views
administrator
administrator
06/26/23

Dr. Elizabeth Henske is a medical oncologist at the Brigham and Women's Hospital and Dana-Farber Cancer Institute and Harvard Medical School in Boston.

In this episode of #KidneyCANDID, Dr. Henske breaks down chromophobe #RCC, a rare subtype of #kidneycancer. She explains how researchers are using the properties of chromophobe tumors to develop specifically targeted therapies.

If you're facing kidney cancer, you're not alone. KidneyCAN has an entire community of patients and caregivers who can talk to you about your experiences and help connect you to expert care. Check out our Patient Resource Center and patient education events at www.kidneycan.org.

Have a KidneyCANDID topic you'd like to see us tackle? Let us know by emailing info@kidneycan.org with KidneyCANDID Topic in the subject line.

—————————————————————————
KidneyCAN works to accelerate cures for kidney cancer by providing patient support and education, encouraging enrollment in clinical trials, advocating for research funding from Congress, and sponsoring collaborative efforts between researchers and medical communities.

To learn more about KidneyCAN: https://kidneycan.org​
Support our work: https://kidneycan.org/donate

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next